Pulmonology Advisor2d
FDA Drug Approval Decisions Expected in April 2025
Treatments for dry eye disease, neuroendocrine tumors, chronic spontaneous urticaria, Barth syndrome, and migraine are under review.
Multiple Sclerosis News Today12h
FDA approves prefilled syringe formulation of Ani’s Cortrophin Gel
The FDA approved a prefilled syringe format for Ani's purified Cortrophin Gel that should ease administration for MS patients ...
PharmaTher receives FDA approval goal date for ketamine
PharmaTher (PHRRF) has received an Amendment Acknowledgement Letter from the U.S. Food and Drug Administration for its New Drug Application for ...
ICON Public Limited Company (ICLR): A Bull Case Theory
We came across a bullish thesis on ICON Public Limited Company (ICLR) on Substack by Oliver | MMMT Wealth. In this article, ...
U.S. News & World Report7d
FDA Approves TNKase for Acute Ischemic Stroke
THURSDAY, March 6, 2025 (HealthDay News) -- The U.S. Food and Drug Administration has approved TNKase (tenecteplase), a ...
Fierce Pharma3d
Neurotech nabs FDA approval to treat rare eye disorder with cell therapy implant Encelto
With a U.S. green light for its encapsulated cell therapy technology in the bag, privately held biotech Neurotech ...
AOL5d
How a new FDA-approved drug can — and can’t — help people with Alzheimer’s
So, what’s really going on? In early 2023, the U.S. Food and Drug Administration (FDA) granted accelerated approval to a new Alzheimer’s drug called Leqembi. (Biogen, a biotechnology company ...
PharmaTher Receives US FDA Approval Goal Date for Ketamine
“I am very pleased with the new FDA approval goal date of June 4, 2025 for our Ketamine drug. We are focused on solving the shortage issue of Ketamine and becoming the leading supplier of Ketamine to ...